Home › Companies › Q32 Bio Inc. › 2025-2026
At Q32 Bio Inc.'s shareholder meeting held June 12, 2026, in the 2025-2026 proxy season, 63 asset managers reported how they voted in their SEC Form N-PX filings, covering 166 separate fund positions. Their filings are grouped here into 8 reported items; because filers word the same ballot item differently, that can be more than the number of items on the ballot. On the most widely held item on that ballot — TO APPROVE, ON A NON-BINDING, ADVISORY BASIS, THE COMPENSATION OF OUR NAMED EXECUTIVE OFFICERS… — Q32 Bio Inc.'s filing reports the proposal as approved, with 95% support of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side). Source: Q32 Bio Inc.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on June 16, 2026.
Download data (CSV): ballot items · votes by manager · column guide.
Compiled from SEC Form N-PX filings and Q32 Bio Inc.’s Form 8-K, filed June 16, 2026 (Item 5.07 on EDGAR). Page generated November 8, 2026.
Meeting of June 12, 2026: 5 items on Q32 Bio Inc.’s Form 8-K, filed June 16, 2026: 2 approved · 3 without a stated outcome.
None.
Material dissent: a director nominee under 80% of the votes cast, say-on-pay under 70%, any other item the board put forward under 80%, or a shareholder proposal with more than 50%, on the company’s own Form 8-K tally. How this is decided
Proxy season: 2024-2025 2025-2026
Explore Q32 Bio Inc. in the interactive database Compare manager voting policies
These tallies are Q32 Bio Inc.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed June 16, 2026 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.
| Ballot item | For | Against | Abstain | Withheld | Broker non-votes | Support (of votes cast) | Reported outcome | Voting standard |
|---|---|---|---|---|---|---|---|---|
| Elect Director: Kathleen LaPorte | 7,187,421 | -- | -- | 1,428,633 | 3,217,746 | 83% | Not verified | — |
| Elect Director: Jodie Morrison | 8,591,626 | -- | -- | 24,428 | 3,217,746 | 99.7% | Not verified | — |
| Elect Director: Arthur Tzianabos, Ph.D. | 8,310,837 | -- | -- | 305,217 | 3,217,746 | 96% | Not verified | — |
| 2. Ratification of the Appointment of Ernst & Young LLP as the Company's Independent Registered Public Accounting Firm for the Fiscal Year Ending December 31, 2026 | 11,821,046 | 7,909 | 4,845 | -- | -- | 99.9% | Approved | — |
| 3. Non-Binding, Advisory Vote on the Compensation of the Company's Named Executive Officers | 8,072,067 | 400,598 | 143,389 | -- | 3,217,746 | 95% | Approved | — |
Source: Q32 Bio Inc., Form 8-K, filed with the SEC on June 16, 2026 — read the filing on EDGAR.
Each item below shows how the 63 asset managers that disclosed a Q32 Bio Inc. vote in their SEC Form N-PX filings actually voted. Share totals are the shares those managers' funds voted, summed across every fund they report. These are reported items, not a count of the ballot: fund filings describe one ballot item in different words. Two descriptions are shown as one item only on evidence — the same text (or one cut short of the other), the same director nominee, or a match to the same row of Q32 Bio Inc.’s own Form 8-K tally — never because they merely read alike. A description that could not be joined that way is listed on its own, so one ballot item can appear more than once.
98% of fund votes cast · no official result
Description as filed by funds: To elect Kathleen LaPorte, Jodie Morrison, and Arthur Tzianabos, Ph.D. as Class II directors to our Board of Directors, each to serve until the 2029 Annual Meeting of stockholders and until his or her successor has been duly elected and qualified, or until his or her earlier death, resignation, or removal: Arthur Tzianabos, Ph.D.
The 7 asset managers below reported 416,821 for, 8,200 withheld. The figure above is FOR ÷ (FOR + AGAINST + WITHHELD) of the shares these managers voted; abstained and unvoted shares are in neither half, and these managers are a subset of all shareholders, not the meeting result.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 305,555 | 0 | 0 | 0 | For |
| Fidelity | 64,878 | 0 | 0 | 0 | For |
| American Century | 33,755 | 0 | 0 | 0 | For |
| BRIDGEWAY FUNDS INC | 12,613 | 0 | 0 | 0 | For |
| Dimensional | 0 | 0 | 0 | 8,200 | Withhold |
| Guggenheim | 13 | 0 | 0 | 0 | For |
| Blackstone Alternative Investment Funds | 7 | 0 | 0 | 0 | For |
98% of fund votes cast · no official result
Description as filed by funds: To elect Kathleen LaPorte, Jodie Morrison, and Arthur Tzianabos, Ph.D. as Class II directors to our Board of Directors, each to serve until the 2029 Annual Meeting of stockholders and until his or her successor has been duly elected and qualified, or until his or her earlier death, resignation, or removal: Jodie Morrison
The 7 asset managers below reported 416,821 for, 8,200 withheld. The figure above is FOR ÷ (FOR + AGAINST + WITHHELD) of the shares these managers voted; abstained and unvoted shares are in neither half, and these managers are a subset of all shareholders, not the meeting result.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 305,555 | 0 | 0 | 0 | For |
| Fidelity | 64,878 | 0 | 0 | 0 | For |
| American Century | 33,755 | 0 | 0 | 0 | For |
| BRIDGEWAY FUNDS INC | 12,613 | 0 | 0 | 0 | For |
| Dimensional | 0 | 0 | 0 | 8,200 | Withhold |
| Guggenheim | 13 | 0 | 0 | 0 | For |
| Blackstone Alternative Investment Funds | 7 | 0 | 0 | 0 | For |
87% of fund votes cast · no official result
Description as filed by funds: To elect Kathleen LaPorte, Jodie Morrison, and Arthur Tzianabos, Ph.D. as Class II directors to our Board of Directors, each to serve until the 2029 Annual Meeting of stockholders and until his or her successor has been duly elected and qualified, or until his or her earlier death, resignation, or removal: Kathleen LaPorte
The 7 asset managers below reported 370,433 for, 54,588 withheld. The figure above is FOR ÷ (FOR + AGAINST + WITHHELD) of the shares these managers voted; abstained and unvoted shares are in neither half, and these managers are a subset of all shareholders, not the meeting result.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 305,555 | 0 | 0 | 0 | For |
| Fidelity | 64,878 | 0 | 0 | 0 | For |
| American Century | 0 | 0 | 0 | 33,755 | Withhold |
| BRIDGEWAY FUNDS INC | 0 | 0 | 0 | 12,613 | Withhold |
| Dimensional | 0 | 0 | 0 | 8,200 | Withhold |
| Guggenheim | 0 | 0 | 0 | 13 | Withhold |
| Blackstone Alternative Investment Funds | 0 | 0 | 0 | 7 | Withhold |
96% Majority: yes · of votes cast
Description as filed by funds: ELECTION OF CLASS II DIRECTOR TO SERVE UNTIL THE 2029 ANNUAL MEETING OF STOCKHOLDERS AND UNTIL HIS OR HER SUCCESSOR HAS BEEN DULY ELECTED AND QUALIFIED, OR UNTIL HIS OR HER EARLIER DEATH, RESIGNATION, OR REMOVAL: ARTHUR TZIANABOS, PH.D.
Q32 Bio Inc.’s own tally for this item (“Elect Director: Arthur Tzianabos, Ph.D.”): 8,310,837 for, 305,217 withheld, per its Form 8-K filed June 16, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 96% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 2 asset managers below reported 15 for, 869 withheld, 1 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 15 | 0 | 1 | 829 | Withhold |
| Advisors' Inner Circle Fund III | 0 | 0 | 0 | 40 | Withhold |
99.7% Majority: yes · of votes cast
Description as filed by funds: ELECTION OF CLASS II DIRECTOR TO SERVE UNTIL THE 2029 ANNUAL MEETING OF STOCKHOLDERS AND UNTIL HIS OR HER SUCCESSOR HAS BEEN DULY ELECTED AND QUALIFIED, OR UNTIL HIS OR HER EARLIER DEATH, RESIGNATION, OR REMOVAL: JODIE MORRISON
Q32 Bio Inc.’s own tally for this item (“Elect Director: Jodie Morrison”): 8,591,626 for, 24,428 withheld, per its Form 8-K filed June 16, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 99.7% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 2 asset managers below reported 885 for.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 845 | 0 | 0 | 0 | For |
| Advisors' Inner Circle Fund III | 40 | 0 | 0 | 0 | For |
Combines 2 wordings of this item as funds reported it.
83% Majority: yes · of votes cast
Description as filed by funds: ELECTION OF CLASS II DIRECTOR TO SERVE UNTIL THE 2029 ANNUAL MEETING OF STOCKHOLDERS AND UNTIL HIS OR HER SUCCESSOR HAS BEEN DULY ELECTED AND QUALIFIED, OR UNTIL HIS OR HER EARLIER DEATH, RESIGNATION, OR REMOVAL: KATHLEEN LAPORTE
Q32 Bio Inc.’s own tally for this item (“Elect Director: Kathleen LaPorte”): 7,187,421 for, 1,428,633 withheld, per its Form 8-K filed June 16, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 83% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 2 asset managers below reported 880 for, 5 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 840 | 0 | 5 | 0 | For |
| Advisors' Inner Circle Fund III | 40 | 0 | 0 | 0 | For |
Combines 6 wordings of this item as funds reported it.
95% Approved · of votes cast
Description as filed by funds: TO APPROVE, ON A NON-BINDING, ADVISORY BASIS, THE COMPENSATION OF OUR NAMED EXECUTIVE OFFICERS; AND
Q32 Bio Inc.’s own tally for this item (“3. Non-Binding, Advisory Vote on the Compensation of the Company's Named Executive Officers”): 8,072,067 for, 400,598 against — passed, per its Form 8-K filed June 16, 2026 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “Proposal No. 3 - Non-Binding, Advisory Vote on the Compensation of the Company's Named Executive Officers: The stockholders of the Company approved, on a non-binding, advisory basis, the compensation of the Company's named executive officers.”
Support: 95% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 306,001 | 399 | 1 | 0 | For |
| Fidelity | 64,878 | 0 | 0 | 0 | For |
| American Century | 33,755 | 0 | 0 | 0 | For |
| BRIDGEWAY FUNDS INC | 12,613 | 0 | 0 | 0 | For |
| Dimensional | 0 | 8,200 | 0 | 0 | Against |
| Advisors' Inner Circle Fund III | 0 | 40 | 0 | 0 | Against |
| Guggenheim | 13 | 0 | 0 | 0 | For |
| Blackstone Alternative Investment Funds | 7 | 0 | 0 | 0 | For |
Fund voting reports, all 8 managers: 417,267 for, 8,639 against, 1 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| ORBIMED ADVISORS LLC | 2,252,987 | 0 | 0 | 0 | For |
| Atlas Venture Life Science Advisors, LLC | 2,092,106 | 0 | 0 | 0 | For |
| Carlyle Group Inc. | 1,102,741 | 0 | 0 | 0 | For |
| Point72 | 865,306 | 0 | 0 | 0 | For |
| MACKENZIE FINANCIAL CORP | 0 | 333,423 | 0 | 0 | Against |
| ARCH Venture Management, LLC | 320,482 | 0 | 0 | 0 | For |
| MONIMUS CAPITAL MANAGEMENT, LP | 0 | 0 | 134,310 | 0 | Abstain |
| ACADIAN ASSET MANAGEMENT LLC | 118,617 | 0 | 0 | 0 | For |
| GEODE CAPITAL MANAGEMENT, LLC | 87,684 | 0 | 0 | 0 | For |
| BlackRock | 83,980 | 0 | 0 | 0 | For |
| PFIZER INC | 74,766 | 0 | 0 | 0 | For |
| Two Sigma | 46,900 | 0 | 0 | 0 | For |
| American Century | 33,755 | 0 | 0 | 0 | For |
| Northern Trust | 23,714 | 0 | 0 | 0 | For |
| Renaissance | 20,775 | 0 | 0 | 0 | For |
| Affinity Asset Advisors, LLC | 18,513 | 0 | 0 | 0 | For |
| MARSHALL WACE, LLP | 0 | 17,208 | 0 | 0 | Against |
| State Street | 17,014 | 0 | 0 | 0 | For |
| BRIDGEWAY CAPITAL MANAGEMENT, LLC | 12,613 | 0 | 0 | 0 | For |
| Vanguard | 12,059 | 0 | 0 | 0 | For |
| Prudential/PGIM | 6,100 | 0 | 0 | 0 | For |
| Ethic Inc. | 0 | 5,278 | 0 | 0 | Against |
| SmartHarvest Portfolios, LLC | 4,918 | 0 | 0 | 0 | For |
| PARAMETRIC PORTFOLIO ASSOCIATES LLC | 4,830 | 0 | 0 | 0 | For |
| MML INVESTORS SERVICES, LLC | 4,735 | 0 | 0 | 0 | For |
Institutional-manager reports, all 59 managers: 7,219,425 for, 366,826 against, 134,310 abstained. Showing the 25 largest; every one is in the interactive database (link above).
Combines 2 wordings of this item as funds reported it.
99.9% Approved · of votes cast
Description as filed by funds: TO RATIFY THE APPOINTMENT OF ERNST & YOUNG LLP AS OUR INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR THE FISCAL YEAR ENDING DECEMBER 31, 2026;
Q32 Bio Inc.’s own tally for this item (“2. Ratification of the Appointment of Ernst & Young LLP as the Company's Independent Registered Public Accounting Firm for the Fiscal Year Ending December 31, 2026”): 11,821,046 for, 7,909 against — passed, per its Form 8-K filed June 16, 2026 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “Proposal No. 2 - Ratification of the Appointment of Ernst & Young LLP as the Company's Independent Registered Public Accounting Firm for the Fiscal Year Ending December 31, 2026: The stockholders ratified the appointment of Ernst & Young LLP as the Company's independent registered public accounting…”
Support: 99.9% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 8 asset managers below reported 425,906 for.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 306,400 | 0 | 0 | 0 | For |
| Fidelity | 64,878 | 0 | 0 | 0 | For |
| American Century | 33,755 | 0 | 0 | 0 | For |
| BRIDGEWAY FUNDS INC | 12,613 | 0 | 0 | 0 | For |
| Dimensional | 8,200 | 0 | 0 | 0 | For |
| Advisors' Inner Circle Fund III | 40 | 0 | 0 | 0 | For |
| Guggenheim | 13 | 0 | 0 | 0 | For |
| Blackstone Alternative Investment Funds | 7 | 0 | 0 | 0 | For |
Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported, shown as a share of the 16,956,415 shares outstanding at the time of that meeting.
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | Vanguard | 1.81% |
| 2 | Fidelity | 0.38% |
| 3 | American Century | 0.20% |
| 4 | BRIDGEWAY FUNDS INC | 0.07% |
| 5 | Dimensional | 0.05% |
| 6 | Advisors' Inner Circle Fund III | <0.01% |
| 7 | Guggenheim | <0.01% |
| 8 | Blackstone Alternative Investment Funds | <0.01% |
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | ORBIMED ADVISORS LLC | 13.29% |
| 2 | Atlas Venture Life Science Advisors, LLC | 12.34% |
| 3 | Carlyle Group Inc. | 6.50% |
| 4 | Point72 | 5.10% |
| 5 | MACKENZIE FINANCIAL CORP | 1.97% |
| 6 | ARCH Venture Management, LLC | 1.89% |
| 7 | MONIMUS CAPITAL MANAGEMENT, LP | 0.79% |
| 8 | ACADIAN ASSET MANAGEMENT LLC | 0.70% |
| 9 | GEODE CAPITAL MANAGEMENT, LLC | 0.52% |
| 10 | BlackRock | 0.50% |
As disclosed to the SEC in Form 13F (quarter-end holdings of 30 large managers), Schedules 13D and 13G (beneficial ownership above 5%) and the company’s own proxy statement (DEF 14A). Each row names its form.
| Holder | % outstanding | Disclosure |
|---|---|---|
| ORBIMED ADVISORS LLC | — | 13D |
| BVF PARTNERS L P/IL | — | 13G |
| Boxer Capital Management, LLC | — | 13G |
| RA Capital Management, L.P. | — | 13G |
| BANK OF AMERICA CORP /DE/ | — | 13G |
| Frazier Life Sciences Public Fund, L.P. | — | 13G |
| Point72 Asset Management, L.P. | — | 13G |
| Opaleye Management Inc. | — | 13G |
| Atlas Venture Fund X, L.P. | — | 13D |
| The Carlyle Group Inc. | — | 13G |
Percentages above are of 16,956,415 shares outstanding, as reported by Q32 Bio Inc. on its Form 10-Q dated May 1, 2026 (see the filing on EDGAR). This is the count contemporaneous with the 2025-2026 meeting, not today’s. Each holding is as of its own filing, which may be dated before or after the meeting.
Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from Q32 Bio Inc.’s 10-Q dated May 1, 2026. This page is a static snapshot rebuilt weekly on November 8, 2026; a live search always shows the current data.
Q32 Bio Inc. proxy season coverage: 2024-2025 · 2025-2026 (this page).
proxyvotesnow.com, “Q32 Bio (QTTB) 2026 Annual Meeting: Vote Results & How Funds Voted”, https://proxyvotesnow.com/company/q32-bio-inc/2026 (version of November 9, 2026). Derived from SEC Form N-PX and Form 8-K filings; tables licensed CC BY 4.0. Licence: CC BY 4.0.